ASND Ascendis Pharma A/S

50

Healthcare [ 2/11 ] | Biotechnology [ 31/156 ]

DK | NASDAQ | Stock

Price
$109.8
Increased by +0.02%
Dollar Volume
26.11 M
ADR%
3.47
Earnings Report Date (estimate)
May 9, 23 (-2.5)
Market Cap.
6.28 B
Shares Float
55.37 M
Shares Outstanding
57.03 M
Beta
0.55
Price / Earnings
-9.93
BPR
69.77
20D Range
103.85 117.40
50D Range
103.85 127.77
200D Range
77.28 134.48
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 22 -3.03
Decreased by -106.12%
 -2.49
Decreased by -8.71%
Aug 10, 22 -1.46
Increased by +41.60%
 -2.13
Increased by +14.77%
May 11, 22 -2.21
Decreased by -88.89%
 -2.00
Decreased by -5.25%
Mar 2, 22 -1.87
Increased by +29.17%
 -2.34
Increased by +8.58%
Nov 10, 21 -1.47
Increased by +36.36%
 -2.29
Increased by +15.64%
Aug 25, 21 -2.50
Decreased by -26.90%
 -2.22
Decreased by -5.68%
May 27, 21 -1.17
Increased by +11.36%
 -1.70
Increased by +18.34%
Mar 10, 21 -2.64
Decreased by -55.29%
 -1.55
Decreased by -45.37%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 15.29 M
Increased by +1.27 K%
 -168.96 M
Decreased by -110.28%
Decreased by -1.11 K%
Increased by +84.69%
Jun 30, 22 6.16 M
Increased by +502.74%
 -81.32 M
Increased by +39.48%
Decreased by -1.32 K%
Increased by +89.96%
Mar 31, 22 6.83 M
Increased by +815.28%
 -125.50 M
Decreased by -99.86%
Decreased by -1.84 K%
Increased by +78.16%
Dec 31, 21 4.90 M
Increased by +815.51%
 -106.06 M
Increased by +23.68%
Decreased by -2.17 K%
Increased by +91.66%
Sep 30, 21 1.11 M
Decreased by -59.63%
 -80.35 M
Increased by +34.00%
Decreased by -7.22 K%
Decreased by -63.49%
Jun 30, 21 1.02 M
Decreased by -28.83%
 -134.37 M
Decreased by -41.55%
Decreased by -13.15 K%
Decreased by -98.89%
Mar 31, 21 746.00 K
Decreased by -66.47%
 -62.79 M
Increased by +0.83%
Decreased by -8.42 K%
Decreased by -195.78%
Dec 31, 20 535.00 K
Decreased by -78.66%
 -138.97 M
Decreased by -72.92%
Decreased by -25.97 K%
Decreased by -710.32%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.